Protea to Acquire VivoPharm for $11.2M | GenomeWeb

NEW YORK (GenomeWeb) – Protea Biosciences today announced that it has entered into an agreement to buy the research services firm VivoPharm for cash and equity.

According to the firm's 8-K filed with the SEC on April 6, Protea will acquire all shares of Hershey, Pa.-based VivoPharm and its subsidiaries for $11.2 million, including $5.4 million in cash and $5.7 million in the form of 570,053 shares of new Series A stock. Upon completion of the deal, VivoPharm will operate as a business unit of Protea, the firm said in a statement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: intellectual property landscape of CRISPR genome editing, and more.

A researcher has been convicted of conspiring to steal genetically engineered rice, Reuters reports.

Harvard Medical School's George Church says a woolly mammoth-elephant hybrid is only a few years away, according to the New Scientist.

Intel is ending its sponsorship of the International Science and Engineering Fair, the New York Times reports.